Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients

Ilknur Alsan Cetin¹, Sıtkı Utku Akay¹ and Meric Sengöz²

Abstract

Background  In this study, we investigated the ability of prostate-specific antigen (PSA) 12 months after (nPSA12) external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) to predict biochemical recurrence-free survival (BRFS), overall survival (OS), and prostate cancer-specific mortality (PCSM) in intermediate- and high-risk prostate cancer patients.

Methods  We retrospectively reviewed the clinical data of 338 intermediate- and high-risk prostate cancer patients treated with EBRT with ADT at our institution between 2000 and 2018. The median radiation dose was 76 Gy, the median initial PSA level was 17 ng/mL (range, 1–228 ng/mL), and the median duration of ADT was 24 months (range, 6–167 months). The median PSA level 1 months after EBRT was 0.06 ng/mL (range, 0–25.6 ng/mL). Univariate and multivariate analyses were performed. Patient survival was assessed using the Kaplan-Meier method and Cox proportional hazards regression analyses.

Results  The median follow-up time was 5 years (range, 1–20 years). Multivariate analysis revealed that nPSA was an independent and significant factor associated with OS, PCSM, and BRFS ($P = 0.008, P = 0.001, P = 0.04$). Furthermore, the time to nPSA12 was an independent predictor of PCSM and BRFS ($P = 0.042, P = 0.021$). Pelvic irradiation was also significantly associated with worse OS and PCSM ($P = 0.004, P = 0.01$). Additionally, age (≤ 70 or > 70 years) and hormone therapy duration (6 months, 1–3 years, or > 3 years) were significantly associated with OS and PCSM, respectively ($P = 0.004, P = 0.02$). For high risk, nPSA and nPSA12 were an independent predictor for BRFS. ($P = 0.021, P = 0.029$)

Conclusion  The nPSA12 level of > 0.06 ng/mL may independently predict worse PCSM and BRFS in intermediate- and high-risk prostate cancer patients undergoing EBRT and ADT. Additionally, for high risk, nPSA > 0.06 ng/mL and nPSA12 > 0.06 ng/mL may independently predict worse BRFS.
Background

According to National Comprehensive Cancer Network (NCCN) clinical practice guidelines, patients with localized prostate cancer can be classified based on their clinical outcomes as low-, intermediate-, and high-risk [1, 2]. Intermediate- and high-risk patients with localized prostate cancer are often treated with definitive external beam radiation therapy (EBRT) combined with androgen deprivation therapy (ADT). Numerous large-cohort phase III trials have demonstrated that the combination of ADT and EBRT can significantly improve prostate cancer-specific mortality (PCSM), distant metastasis (DM), and biochemical recurrence (BR) rates [3–7].

The measurement of serum prostate-specific antigen (PSA) levels is an invaluable biochemical method for prostate cancer screening, treatment response monitoring, and disease recurrence detection. The nadir in prostate-specific antigen (nPSA) after radiotherapy (RT) has been shown to predict BR, DM, cause-specific mortality (CSM), and overall mortality (OM) [8–13]. Additionally, mounting evidence suggests that time-limited measures of PSA are independent early predictors of BR and DM in patients undergoing definitive EBRT [14–16]. However, the prognostic value of nPSA in prostate cancer patients treated with concurrent ADT and EBRT remains unclear.

The aim of this study was to determine whether a 12-month post-treatment nPSA (nPSA12) cutoff value of 0.06 ng/mL can serve as an early predictor of biochemical recurrence-free survival (BRFS), PCSM, and overall survival (OS) in prostate cancer patients treated with concurrent ADT and EBRT.

Methods

We retrospectively reviewed the clinical data of 338 intermediate- and high-risk prostate cancer patients who underwent radiotherapy combined with ADT between 2000 and 2018 at our institution. All patients had biopsyc-confirmed adenocarcinoma of the prostate and underwent serum PSA testing before treatment. The T stage was determined based on a digital rectal examination. Based on NCCN guidelines, patient risk was classified as intermediate or high. Patient characteristics, including the clinical stage, are shown in Table 1.

All patients were treated with either high-dose 3-dimensional conformal radiation therapy (3DCRT) or volumetric-modulated arc therapy, delivering 70–78 Gy in 28–39 fractions. For intermediate-risk patients, the clinical target volume (CTV) included in the prostate and the seminal vesicles, and 54 Gy was delivered in the first phase of treatment. In the second phase, the dose delivered to the prostate was increased to 70–76 Gy. For high-risk patients, the CTV included the prostate, seminal vesicles, and pelvic lymph nodes; 54 Gy delivered in the first phase of treatment. In the second phase, the dose was increased to 74–78 Gy. The risk of lymph node involvement was calculated according to the Roach formula, and patients with a high risk (>15%) of lymph node metastasis received pelvic radiation. The dose was typically prescribed at the 95% isodose of the beam arrangement and was normalized so that the planning treatment volume was included within the 95% isodose line. All patients were treated with 6 MV photons and received neoadjuvant or concurrent ADT. All patients were also treated with luteinizing hormone-releasing hormone agonists (Goserelin 10.8 mg/3 months, leuprolide acetate 11.25 mg/3 months or 22.5 mg/3months) plus nonsteroidal antiandrogens (bicalutamide 50 mg once daily, orally administered for 1 month). Typically, intermediate-risk patients underwent ADT for 6 months, whereas high-risk patients received ADT for 1–3 years. Neoadjuvant ADT was preferred in patients with large prostate tumors.

The treatment response was monitored by serum PSA testing every 3 months during ADT. Patients had the PSA value of at least 4 after treatment. Patients were followed-up every 3 months for the first 2 years, every 6 months for the following 3 years, and annually thereafter. We defined nPSA as the lowest PSA achieved after treatment. Time to nPSA was defined as the time from treatment initiation to nPSA achievement. BR was defined as a PSA level of at least 2 ng/mL above the nPSA, as per the Phoenix BR definition. Tumor metastases were detected radiographically, and the cause of death was recorded. We collected at least 4 post-treatment PSA values for each patient. nPSA12 was defined as a PSA level of 0.06 ng/mL achieved in the first year of radiotherapy completion. All patients were followed-up for at least 1 year.

BRFS, PCSM, cancer-specific survival (CSS), and OS were determined from the date of RT completion, and patients were stratified based on nPSA12 levels (≤0.06 ng/mL or >0.06 ng/mL). Survival time was defined as the time between the last radiotherapy session and the last follow-up or death. OS was defined as the time between disease diagnosis and the follow-up or death. Patient survival was analyzed using the Kaplan-Meier method and the log-rank test. Univariable and multivariable Cox regression analyses were performed to assess the prognostic value of nPSA12 levels. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. All statistical analyses were conducted using SPSS version 22.0 (IBM Corp., Armonk, NY). P-values<0.05 were considered statistically significant.
| Table 1  | Patient characteristics, treatment, and univariate analysis results |
|----------|---------------------------------------------------------------------|
|          | Number of patients (N = 338) (%) | OS          | PCSM         | BRFS         |
|          |                                   | P value     | P value      | P value      |
| Age      | Median 71(50–85)                  | 0.003       | 0.4          | 0.16         |
|          | ≤70 157(46-4)                     |             |              |              |
|          | >70 181(53.6)                     |             |              |              |
| Comorbidity | no 120(35.7)                | 0.5        | 0.33         | 0.023        |
|          | yes 218(64.3)                    |             |              |              |
| % Positive biopsies | <0.5 154(45.6)            | 0.9        | 0.01         | 0.3          |
|          | ≥0.5 184(54.4)                   |             |              |              |
| % Tumor volume | <50% 150(44.4)           | 0.8        | 0.006        | 0.07         |
|          | ≥50% 188(55.6)                   |             |              |              |
| Gleason score | <7 90(26.6)               | 0.27       | 0.03         | 0.004        |
|          | 7 154(45.6)                      |             |              |              |
|          | > 7 94(27.8)                     |             |              |              |
| Histological grade group | 1 (≤ 6 GS) 91(26.9)      | 0.31       | 0.1          | <0.0001      |
|          | 2 (3 + 4 GS) 95(28.1)           |             |              |              |
|          | 3 (4 + 3 GS) 58(17.2)           |             |              |              |
|          | 4 (8 GS) 48(14.2)               |             |              |              |
| Risk Group | intermediate 131(38.8)      | 0.69       | 0.045        | 0.005        |
|          | high 207(61.2)                  |             |              |              |
| Initial PSA ng/ml | <10 75(30)            | 0.38       | 0.44         | 0.034        |
|          | 10–20 110(32.5)                |             |              |              |
|          | >20 153(45.5)                   |             |              |              |
| Clinical stage | T1 49(14.5)            | 0.6        | 0.09         | 0.9          |
|          | T2 251(74.3)                   |             |              |              |
|          | T3 34(10.2)                    |             |              |              |
|          | T4 4(1)                        |             |              |              |
| HT use   | Neoadjuvant HT 271(80)         | 0.047      | 0.3          | 0.7          |
|          | concomitant 59(17.5)           |             |              |              |
|          | Adjuvant 8(2.5)                |             |              |              |
| HT period | 6 month 89(26.3)            | 0.17       | 0.001        | 0.09         |
|          | 1–3 year 206(60.9)             |             |              |              |
|          | > 3 year 43(12.7)              |             |              |              |
| RT dose  | 70 Gy 56(16.6)                 | 0.68       | 0.26         | 0.001        |
|          | 70-76 Gy 205(60.7)             |             |              |              |
|          | >76 77(22.8)                   |             |              |              |
| RT field | Prostate 265(78.4)              | 0.006      | <0.0001      | <0.0001      |
|          | Pelvis 73(21.6)                 |             |              |              |
Table 1 (continued)

|              | Number of patients (N = 338) (%) | OS   | PCSM  | BRFS  |
|--------------|----------------------------------|------|-------|-------|
|              |                                  | P value | P value | P value |
| RT Technic  |                                  | 0.1  | 0.14  | <0.0001 |
| 3DCRT       | 208(61.5)                        |       |       |       |
| IMRT (VMAT) | 130(38.5)                        |       |       |       |
| PSA nadir (ng/mL) |                               | 0.002 | <0.0001 | <0.0001 |
| ≤0.06       | 269(79.6)                        |       |       |       |
| >0.06       | 56(16.6)                         |       |       |       |
| Unknown     | 13(3.8)                          |       |       |       |
| Time to nadir PSA |                               | 0.72  | 0.017 | 0.003 |
| <12 month   | 234(69.2)                        |       |       |       |
| ≥12 month   | 92(26.9)                         |       |       |       |
| unknown     | 13(3.8)                          |       |       |       |

BOS: Overall survival, PCSM: cancer-specific survival, RFS: biochemical recurrence-free survival, PSA: prostate-specific antigen, HT: hormonotherapy, RT: radiotherapy, 3DCRT: three-dimensional conformal radiotherapy, IMRT: Intensity modulated radiotherapy, VMAT: Volumetric Modulated Arc Therapy

Results

The median follow-up time after RT completion was 5 years (range, 1–20 years). Univariate analyses revealed that advanced age (>70 years) (SE=11.4, 95%CI=139.5-184.4, P=0.003), concurrent hormone therapy (SE=11.4, 95%CI=139.5-184.4, P=0.04), pelvic irradiation (SE=11.4, 95%CI=139.5-184.4, P=0.006), and nPSA >0.06 ng/mL (SE=9.8, 95%CI=146.7-185.2, P=0.002) were significantly associated with poor OS. Positive biopsy (≥50%) (SE=5.9, 95%CI=199.8-223.3, P=0.01), tumor size (≥50%) (SE=5.9, 95%CI=201.6-224.7, P=0.006), Gleason score (>7) (SE=5.8, 95%CI=200.6-223.4, P=0.03), high risk (SE=5.8, 95%CI=200.6-223.4, P=0.045), prolonged hormone therapy (>3 years) (SE=5.8, 95%CI=200.6-223.4, P=0.001), pelvic irradiation (SE=13, 95%CI=79.2-130.7, P=0.0001), nPSA >0.06 ng/mL (SE=20.7, 95%CI=135.3-216.6, P<0.0001), and prolonged time to nPSA (>12 months) (SE=5.9, 95%CI=199.5-222.9, P=0.017) were significantly associated with poor CSS (Fig. 1).

Comorbidities (SE=14.8, 95%CI=177.8-236.1, P=0.023), Gleason score (>7) (SE=15.9, 95%CI=175.7-238.2, P=0.004), histological grade (grades 4 and 5) (SE=15.9, 95%CI=175.7-238.2, P<0.0001), high risk (SE=15.9, 95%CI=175.7-238.2, P=0.005), initial PSA levels (>20 ng/mL) (SE=15.9, 95%CI=175.7-238.2, P=0.034), RT dose (>76 Gy) (SE=15.9, 95%CI=175.7-238.2, P=0.001), pelvic irradiation (SE=15.9, 95%CI=175.7-238.2, P<0.0001), IMRT technique (SE=15.9, 95%CI=175.7-238.2, P<0.0001), nPSA >0.06 ng/mL (SE=15.9, 95%CI=175.6-238.3, P<0.0001), and prolonged time to nPSA (>12 months) (SE=15.9, 95%CI=175.6-238.3, P=0.003) were significantly worse associated with BRFS (Table 1; Fig. 2).

Multivariate analyses revealed that nPSA ≤0.06 ng/mL was independently and significantly better associated with PCSM (P=0.042) and BRFS (P=0.021). RT small (prostate) field prostate was significantly better associated with OS (P=0.004) and PCSM (P=0.01). Furthermore, age ≤70 was independently associated with OS (P=0.004) and hormone therapy period (6 months) was independently better associated with PCSM (P=0.02; Table 2).

In univariate analysis and multivariate analysis, intermediate and high risk PC were analyzed separately. For intermediate risk, statistically significant difference was found in nPSA for OS, PCSM, BRFS (P=0.027, P<0.0001, P=0.041). In addition, statistically significant difference was found in nPSA for OS in % positive biopsies, % tumor volume and nPSA12 (P=0.028, P<0.003, P=0.021). For high risk, statistically significant difference was found in nPSA for OS, PCSM, BRFS (P=0.034, P<0.0001, P=0.005). In addition, statistically significant difference was found for OS in age (P=0.02) and for BRFS in RT dose (P=0.037), nPSA12 (P=0.03). nPSA ≤0.06 ng/mL (P=0.021) and nPSA12 (time to nPSA<12 month) (P=0.029) were found to be independent and significantly better predictive factors for BRFS in multivariate analysis.

The 10- and 15-year cumulative incidences of PCSM were 88.8% and 74%, respectively. The 10- and 15-year cumulative incidences of BRFS were 84.3% and 69.4%, respectively. For nPSA12 ≤0.06 ng/mL, the 10- and 15-year cumulative incidences of PCSM and BRFS were 96.5%, 87.2% and 99.3%, 72.5% respectively. Grades 1 and 2 rectal toxicity were observed in 80 (23%) and 18 (5%) patients. Moreover, grades 1 and 2 late urinary toxicity were observed in 180 (53%) and 20 (6%) patients. No cases of severe toxicity (grades 3 and 4) were observed. Erectile function was affected in 113 (33%) patients.

Discussion

In this study, we found that nPSA levels of >0.06 ng/mL within 12 months after ADT and EBRT predicted worse clinical outcomes in intermediate- and high-risk prostate
cancer patients. Importantly, nPSA12 > 0.06 ng/mL was significantly associated with poor PCSM, and BRFS. Similarly, pelvic irradiation, >70 years of age, and prolonged (>3 years) hormone therapy were associated with poor OS and PCSM.

The relationship between BRFS and different nPSA levels has been previously investigated [2, 8, 17]. Patel et al. [20] reported a strong association between an early post-RT PSA level of ≥0.09 ng/mL and high risks of BF, DM, PCSM, and death from all causes. Geara et al. [21] found that an nPSA level of 0.06 ng/mL was an independent
predictor of BFS in patients with intermediate- or high-risk prostate cancer undergoing definitive EBRT and ADT. Consistently, we found that nPSA levels >0.06 ng/mL were associated with worse OS, PCSM, and BRFS.

Cavanaugh et al. [22] demonstrated a strong association between PSA levels and BR, CSM, and OM. Alcantara et al. [15] identified nPSA12 (≤2 versus >2 ng/mL) as an early predictor of BF, DM, and mortality, independent of RT dose and outcome determinants after RT. 10-year DM rates for nPSA12 ≤2 versus >2 ng/mL were 4% versus 19% (P < 0.0001). Ray et al. [14] a total of 4839 patients were treated for Stage T1-T2 prostate cancer with RT and without hormone therapy. 8-year rate of PSA-DFS, DMFS, and OS in patients with a trough PSA12 (≤2.0 ng/mL or >2 ng/mL) 55%, 95% and 73% respectively or 40%, 88% and 69% respectively. In the study of Ogawa et al. [23] 84 patients with localized prostate cancer were treated with RT and hormone therapy. 3-year PFS rate in patients with nPSA12 levels <0.5 ng/mL and patients with nPSA12 levels ≥0.5 ng/mL were 96% and 44%, respectively (P < 0.0001). In this study, for nPSA12 (≤0.06 ng/mL or >0.06 ng/mL), the 8 year incidences of PCSM and BRFS were 91.1%, 92% respectively or 83.2%, 65.9% respectively. We found that nPSA12 was an independent predictor for PCSMS, BRFS in intermediate- and high-risk prostate cancer patients after ADT and EBRT.

The clinical usefulness of pelvic irradiation in patients with a high risk of lymph node metastasis remains controversial. In this study, we found that pelvic irradiation worsened patient survival. Patients with high risk and receiving pelvic RT may have poorer survival as they have a more locally advanced stage. For this reason, PCSM at intermediate risk prostate cancer patients was 94.6%-81.1% at 10–15 years, while it was 83.8%-70.8% at high risk prostate cancer patients (p = 0.04). In addition, Prostate cancer is more common among the elderly, especially in older men with comorbidities. Here, we found that comorbidities were the cause of approximately 70% of all deaths.

Numerous randomized studies have shown that the combination of prolonged hormone therapy (1–3 years) with RT may benefit high risk prostate cancer patients. In this study, we found that hormone therapy for more than 3 years led to worse PCSM. This can be explained by the fact that these patients are very high risk patients.

### Conclusion

In conclusion, our findings suggest that nPSA12 levels of >0.06 ng/mL within 12 months after ADT and EBRT may be a useful prognostic factor of worse survival outcomes in intermediate- and high-risk prostate cancer patients.

### List of abbreviations

- **OS**: Overall survival
- **PCSM**: Prostate cancer specific mortality
- **BRFS**: Biochemical recurrence-free survival
- **HT**: Hormonotherapy
- **RT**: Radiotherapy
- **HR**: Hazard ratio

### Acknowledgements

None.

### Authors' contributions

IAC wrote the manuscript. SUA completed data collection. MS reviewed the manuscript.

### Funding

This research received no specific grant from any funding agency in the public, commercial or not for profit sectors.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Declarations

**Ethics approval and consent to participate**

This retrospective study was conducted in compliance with the principles of the Helsinki declaration and informed consent was obtained from each patient. Ethical approval for this study was obtained from the Ethics Committee of Marmara University (Approval number: 09.2019.384).

### Table 2 Multivariate analysis results showing the prognostic value of different clinicopathological parameters

|                | OS |          | PCSM |          | BRFS |          |
|----------------|----|----------|------|----------|------|----------|
|                | HR | p        | HR   | p        | HR   | p        |
| **Age**        |    |          |      |          |      |          |
| Age            | 1.9(1.2–3.1) | 0.004 | 2.8(1.1–6.9) | 0.02 | 0.5(1.6–1.8) | 0.3 |
| **RT Period**  |    |          |      |          |      |          |
| RT Period      | 2.1(1.1–3.9) | 0.015 | 3.8(1.3–10) | 0.01 | 0.6(0.2–1.9) | 0.45 |
| **RT Field**   |    |          |      |          |      |          |
| RT Field       | 1.9(1.1–3.1) | 0.008 | 3.9(1.7–9.3) | 0.001 | 2.0(0.9–4.1) | 0.04 |
| **PSA Nadir**  |    |          |      |          |      |          |
| PSA Nadir      | 0.9(0.6–1.6) | 0.952 | 2.4(1.5–6.6) | 0.042 | 2.0(1.1–4.0) | 0.021 |

OS: Overall survival, PCSM: prostate cancer specific mortality, BRFS: biochemical recurrence-free survival, HT: hormone therapy, RT: radiotherapy, HR: hazard ratio.
Consent for publication
Not applicable.

Competing interests
None declared.

Author details
1Faculty of Medicine, Department of Radiation Oncology, Marmara University, Fevzi Cakmak Mah., Muhsin Yazıcıoglu Cd. No 10, 34899 Pendik, Istanbul, Turkey
2Department of Radiation Oncology, Acıbadem University, Istanbul, Turkey

Received: 5 November 2020 / Accepted: 20 October 2022
Published online: 15 November 2022

References

1. D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:1763–72.

2. Zelefsky MJ, Lysses O, Fuchs W, Tuminar S, Ling CC, et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol. 1998;16:3380–5.

3. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RT0G 8610. J Clin Oncol. 2008;26:585–91.

4. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–7.

5. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Stame G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol. 2010;11:1066–73.

6. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez MA, et al. High-dose radiotherapy with short-term or long-term androgen suppression in localised prostate cancer (RAT01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:320–7.

7. Pilepich MV, Winter K, Lawton CA, Kirsch RE, Wolkov HB, Movas B, et al. Androgen suppression adjunctive to definitive radiotherapy in prostate cancer: randomised comparison of prostate cancer noma long-term results of phase III RT0G 85 – 31. Int J Radiat Oncol Biol Phys 2005; 61:1265-90.

8. Zietman AL, Tibbs MK, Dallow KC, et al. Use of PSA nadir to predict subse-
quent biochemical outcome after external beam radiotherapy for T1-2 adeno-
carcinoma of the prostate. Radiother Oncol. 1996;40:159–62.

9. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002;54:677–85.

10. Critz FA, Williams WH, Holladay CT, et al. Post-treatment PSA c or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology. 1999;54:96–78.

11. Ray ME, Thames HD, Levy LB, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006;64:1140–50.

12. Hanlon AL, Diratzouzian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:297–303.

13. Pollack A, Hanlon AL, Mows B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:19–23.

14. Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, et al. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. 2006;68:1257–62.

15. Alcántara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer. 2007;109(1):41–7. doi:https://doi.org/10.1002/cncr.22341.

16. Zelefsky MJ, Yarnada WS, Kollmeier MA, Cox B, Park J. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys. 2009;75:1350–6.

17. Lee WR, Hanlon A, Hanks GE. Prostate specific antigen nadir following exter-
nal beam radiotherapy for clinically localized prostate cancer: the relation-
ship between nadir level and disease-free survival. J Urol. 1996;156:450–3. doi:https://doi.org/10.1016/0022-5347(96)010032.

18. Tseng YD, Chen M, Beard C, Martin N, Orio PF, Loffredo M, et al. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all-cause mortality. J Urol. 2012;187(6):2068–73.

19. D’Amico AV, Chen M, Castro MD, Loffredo M, Lamb DS, Steigler A, et al. Surrogate endpoints for prostate cancer-specific mortality after radio-
therapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 2012;13(2):189–95.

20. Patel MA, Kollmeier M, McBride S, Gorovets D, Varghese M, Chan L, et al. Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy. Radiother Oncol. 2019;140:34–40. doi:https://doi.org/10.1016/j.radonc.2019.04.003.

21. Geera FA, Bulbul M, Khrauli RB, Andraos TY, Abboud M, Al Mousa A, et al. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radio-
therapy and androgen deprivation. Radiat Oncol. 2017;12(1):149. doi:https://doi.org/10.1186/s13014-017-0884-y.

22. Cavanaugh SJ, Fuller CD, Kupelian PA, et al. Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. Prostate Cancer Prost tic Dis. 2005;8:353–8.

23. Ogawa K, Nakamura K, Sasaki T, Onishi H, Koizumi M, Shoyama Y, et al. Japa-
nese Patterns of Care Study Working Subgroup of Prostate Cancer. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):599–65. doi: https://doi.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/zAyiMVR.